Home

Articles from Medicenna Therapeutics Corp.

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least the middle of calendar 2026
By Medicenna Therapeutics Corp. · Via GlobeNewswire · August 1, 2025
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp
By Medicenna Therapeutics Corp. · Via GlobeNewswire · July 31, 2025
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least mid-2026
By Medicenna Therapeutics Corp. · Via GlobeNewswire · June 26, 2025
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME)
By Medicenna Therapeutics Corp. · Via GlobeNewswire · April 30, 2025
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI) or with historically low responses to ICI
By Medicenna Therapeutics Corp. · Via GlobeNewswire · April 28, 2025